ArticleBMC infectious diseases2026
HBsAg seroreversion after pegylated interferon alpha induced HBsAg seroclearance in patients with chronic hepatitis B: a real-world cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of different pegylated interferon alpha (Peg-IFNα) treatment strategies on the recurrence after Hepatitis B surface antigen (HBsAg) seroclearance has not yet been adequately elucidated.
aimsThis real-world study was conducted to compare the risk of HBsAg seroreversion after HBsAg seroclearance in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB) receiving Peg-IFNα-2b combination therapy with nucleos(t)ide analogues (NAs) and Peg-IFNα-2b monotherapy, and further to identify predictors by developing a risk prediction model.
methodsUsing a retrospective cohort design, 438 enrolled participants were partitioned to training and validation cohorts. The non-zero coefficient variables were identified via least absolute shrinkage and selection operator - Cox proportional hazards regression (Lasso-Cox), with subsequent multivariate Cox analysis establishing the predictive algorithm. Model performance underwent evaluation through calibration curves and time-dependent receiver operating characteristic (time-dependent ROC) analysis.
resultsThe cumulative HBsAg seroreversion rates at 48 and 96 weeks were 15.7% and 18.9% in the combination group and 21.2% and 26.4% in the monotherapy group, respectively, with no statistically significant difference between groups.The final model incorporated two predictors: baseline HBsAg level (HR = 1.507, 95%CI: 1.081-2.101, P = 0.016), and end-of-treatment (EOT) hepatitis B surface antibody (HBsAb) level (HR = 0.973, 95%CI: 0.960-0.986, P < 0.001). The optimal cut-off value of HBsAb titer at EOT calculated by ROC curve was 32.28 IU/L. The calibration curves delineated favorable consistency for the nomogram model. Time-dependent ROC curves presented better discriminatory ability, with area under the curve (AUC) values of 0.781, 0.800, 0.820 and 0.827 at 12, 24, 48, and 96 weeks in the training set.
conclusionsThe observed durability of HBsAg negativity was not significantly improved with Peg-IFNα combination therapy compared with monotherapy. Baseline HBsAg and EOT-HBsAb levels may support individualized recurrence risk stratification. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.